Ultra-Scan's TouchLink Solution Allows CROs to Accurately Identify Patients and Ensure Study Integrity.
Buffalo, NY-June 13, 2006-As federal regulations become stricter, it is important for clinical research organizations (CROs) to take the necessary measurements and precautions to accurately identify study participants and their eligibility for clinical trial participation. Ultra-Scan Corporation, an identity management solutions provider, will showcase its TouchLink Identity Management Software at the Drug Information Association's 42nd Annual Meeting in Philadelphia. Researchers and trial administrators will have the opportunity learn more about this revolutionary technology in support of clinical trials.
Ultra-Scan's TouchLink Identity Management Software offers clinical research organizations an accurate and cost-effective solution for establishing, managing and repeatedly validating subject identity. TouchLink provides standalone or integrated identification utilizing Ultra-Scan's patented ultrasonic fingerprint identification system to quickly and easily enroll and identify a subject population within a single site or across multiple sites and facilities. From screening through post-study follow-up, TouchLink can positively impact study results and enhance subject safety by providing essential identity validation. In turn, this ensures that each authorized subject is properly tested, treated, monitored and reimbursed during clinic and study encounters.
TouchLink is supported by Ultra-Scan's patented Livescan Ultrasonic Identification Systems (LUIS™), a biometric technology that uses ultrasound, high frequency sound waves, to capture high quality fingerprint images across all user populations and operational environments. LUIS can "see through" dirt, newsprint, hand lotions and other common finger contaminants, guaranteeing unsurpassed accuracy, reliability and ease of use.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.